Due to health issues, this site is no longer maintained and will be shut down shortly.

SS:CALTX Calliditas Therapeutics AB

Calliditas Therapeutics AB (publ) operates as a specialty pharmaceutical company in Stockholm, Sweden. It focuses on developing pharmaceutical products for patients with an unmet medical need in niche indications, in which the company can partially or completely participate in the commercialization. The company focuses on the development and commercialization of the product candidate Nefecon, a unique formulation optimized to combine a time lag effect with a concentrated release of the active substance budesonide, within a designated target area. This patented, locally acting formulation is intended for treatment of patients with the inflammatory renal disease IgA nephropathy. Calliditas Therapeutics AB (publ) intends to take Nefecon through a global Phase 3 study to commercialization. The company was founded in 2004 and is headquartered in Stockholm, Sweden.This company has ADRs that trade in the U.S. as the symbol CALT.

95.40 SEK
As of 03/08/2023

Security Information
Category1:  Global Equity
Category2:  Common stocks
Category3:  Developed markets ex-US
GICS sector:  Health Care
Index country:  Sweden
Country of incorporation:  Sweden
IPO date:  01/01/1900
Stock exchange:    Nasdaq Omx Nordic
Exchange country:   Sweden
Market cap:   0 SEK
Current dividend yield:   0.00%
Sedol:      BDFXJ96

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy